阿哌沙班预防免疫调节剂治疗骨髓瘤患者血栓栓塞:Myelaxat 2期先导研究
该前瞻性2期先导研究纳入104例接受来那度胺或沙利度胺治疗的骨髓瘤患者,给予阿哌沙班2.5 mg每日两次预防6个月。观察到2例静脉血栓事件(均为深静脉血栓,其中1例无症状近端、1例有症状远端,均发生在因来那度胺所致血小板减少而停用阿哌沙班14天后),无肺栓塞或动脉心血管事件;报告1例大出血和11例临床相关非大出血。作者认为这些数据需在随机大型研究中证实。
要点
- 104例骨髓瘤患者接受阿哌沙班2.5 mg每日两次预防6个月,其中11例一线、93例复发。
- 观察到2例静脉血栓事件(1例无症状近端DVT、1例有症状远端DVT),均发生于停用阿哌沙班14天后。
- 无肺栓塞或动脉心血管事件;报告1例大出血和11例临床相关非大出血。
核心结论
- 在接受来那度胺或沙利度胺治疗的骨髓瘤患者中,使用阿哌沙班2.5 mg每日两次预防6个月,观察到2例静脉血栓事件和1例大出血、11例临床相关非大出血;作者指出这些数据需在随机大型研究中证实。
研究设计与样本
- 前瞻性2期先导研究,纳入104例骨髓瘤患者(平均年龄69.8±7.8岁),其中11例一线接受美法仑-泼尼松-沙利度胺、93例复发接受来那度胺-地塞米松。
- 干预为阿哌沙班2.5 mg每日两次,持续6个月。
- 登记静脉事件(肺栓塞、有症状近端或远端深静脉血栓、系统双侧近端压迫超声检测的无症状近端事件)、动脉血栓事件及出血事件(ISTH 2005标准)。
主要发现
- 共观察到2例静脉血栓事件:1例无症状近端深静脉血栓和1例有症状远端深静脉血栓,均发生在因来那度胺所致血小板减少而停用阿哌沙班14天后。
- 未报告肺栓塞或动脉心血管事件。
- 报告1例大出血和11例临床相关非大出血(CRNM)。
关键数值与推荐
- 阿哌沙班给药方案为2.5 mg每日两次,持续6个月。
- 静脉血栓事件2例(无症状近端DVT 1例、有症状远端DVT 1例),均发生于停用阿哌沙班14天后。
- 大出血1例,临床相关非大出血11例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出这些数据必须在随机大型研究中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The risk of venous thromboembolism (VTE) is higher in myeloma patients receiving immunomodulatory compounds. A VTE prophylaxis using low-molecular-weight heparin or aspirin is therefore proposed. Apixaban is an oral direct anti-Xa. Several studies have shown the efficacy and safety of apixaban in VTE prophylaxis compared to enoxaparin. The objective of this prospective phase 2 pilot study was to assess the risk of VTE and bleeding in patients with myeloma treated with immunomodulatory compounds lenalidomide (len) or thalidomide (thal), using apixaban in a preventive scheme. Myeloma patients requiring Melphalan-Prednisone-Thalidomide in the first line, or Lenalidomide-Dexamethasone in the relapse setting received apixaban, 2.5 mg x 2/day for 6 months. Venous (pulmonary embolism-PE, or symptomatic proximal or distal deep vein thrombosis-DVT, or all proximal asymptomatic events detected by systematic proximal bilateral compression ultrasound) or arterial thrombotic events, and bleeding events (ISTH 2005) were registered. One hundred and four patients were enrolled (mean age 69.8 ± 7.8 years), 11 in first line and 93 in relapse. Two venous thrombotic events were observed, for example, an asymptomatic proximal DVT and a symptomatic distal DVT, in the context of apixaban stopped 14 days before, due to lenalidomide-induced thrombocytopenia. No PE or arterial cardiovascular events were reported. Only one major and 11 CRNM hemorrhages were reported. These data must now be confirmed on a randomized large study.
引用
- Pegourie B, Karlin L, Benboubker L, et al. Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol. 2019. PMID: 30859608. doi:10.1002/ajh.25459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。